痛風為體內尿酸代謝異常，造成尿酸鈉結晶沉澱在關節中所引發的關節炎。大量嗜中性球浸潤到關節腔中為造成痛風發炎反應的主要原因，而活化的巨噬細胞和肥大細胞是促使嗜中性球浸潤的可能因素，此外，肥大細胞的活化可能與補體系統有關。芝麻油在多種動物模式中具有抗發炎作用，然而芝麻油對痛風發炎反應的影響尚未有相關研究。本研究目的為探討芝麻油對痛風所引起發炎反應之保護作用。實驗採用空腔動物模式，以尿酸鈉鹽結晶誘發痛風的發炎反應，並分別在誘導前六小時、誘導後六小時以及誘導前連續七天每日灌食芝麻油。研究結果顯示不論是事先還是事後給予單一劑量芝麻油，都能有效減緩尿酸鈉鹽引起的前發炎因子，如腫瘤壞死因子α、介白質1和介白質6的產生和白血球蓄積情形，然而連續七天每日灌食芝麻油並沒有顯著效果。進一步在單一劑量芝麻油的治療實驗結果發現，芝麻油能顯著抑制嗜中性球浸潤、減少肥大細胞數量、介白質4含量以及 NF-B活性；芝麻油也可以顯著降低補體裂解蛋白C3a、C5a和免疫球蛋白IgG的生成，但對巨噬細胞的活化沒有影響。總結，單一劑量芝麻油可能藉由抑制肥大細胞的活化，而有效減緩尿酸鈉鹽結晶所引起之痛風發炎反應，而連續七天每日補充之麻油則無法有效抑制痛風發炎反應。

Gout is an inflammatory arthritis induced by deposition of monosodium urate monohydrate (MSU) crystals in articular joints. Joint neutrophil infiltration is important in the pathogenesis of gouty inflammation, regulated by activated macrophage and mast cell. In addition, mast cell activation may be associated with complement system. Sesame oil shows potent anti-inflammatory effect in various disease models. However, the effect of sesame oil on gouty inflammation has never been investigated. The aim of this study was to investigate the effect of sesame oil on MSU-induced gouty inflammation in an air pouch animal model. Sesame oil was gavaged in three methods: (1) single dose 6 h before, (2) single dose 6 h after, and (3) daily supplement for 7 days before MSU treatment. Sesame oil significantly decreased MSU-induced tumor necrosis factor-, interleukin (IL)-1, IL-6 production and inflammatory cell recruitment in air pouch in the single dose 6 h before and single dose 6 h after models; however, it was ineffective in 7 days gavage model. Furthermore, sesame oil significantly inhibited neutrophil infiltration and reduced the mast cell density, IL-4 level, and NF-B activity in mast cells in the single dose 6 h after MSU treatment model. Sesame oil also significantly decreased the production of complement cleavage product (C3a and C5a) and immunoglobulin IgG, but no activation of macrophage. In conclusion, sesame oil attenuated MSU-induced gouty inflammation by inhibiting mast cell activation; however, no effect was found in the 7-day supplement model.

1. Abramson S, Hoffstein ST, Weissmann G. 1982. Superoxide anion generation by human neutrophils exposed to monosodium urate. Arthritis Rheum 25:174-180.
2. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. 1987. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17:301-304.
3. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. 2002. Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403-2406.
4. Asokan S, Emmadi P, Chamundeswari R. 2009. Effect of oil pulling on plaque induced gingivitis: a randomized, controlled, triple-blind study. Indian J Dent Res 20:47-51.
5. Becker MA. 1988. Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am 14:377-394.
6. Befus AO, Pearce FL, Gauldie J, Horsewood P, Bienenstock J. 1982. Mucosal mast cells. I. Isolation and functional characterization of rat intestinal mast cells. J Immunol 128:2475-2479.
7. Benedek TG, Rodnan GP. 1982. A brief history of the rheumatic diseases. Bull Rheum Dis 32:59-68.
8. Biedermann T, Kneilling M, Mailhammer R, Maier K, Sander CA, Kollias G, Kunkel SL, Hültner L, Röcken M. 2000. Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441-1452.
9. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP. 1999. IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A 96:8080-8085.
10. Bober LA, Waters TA, Pugliese-Sivo CC, Sullivan LM, Narula SK, Grace MJ. 1995. IL-4 induces neutrophilic maturation of HL-60 cells and activation of human peripheral blood neutrophils. Clin Exp Immunol 99:129-136.
11. Budowski P. 1964. Recent research on sesamin, sesamolin, and related compounds. J Am Oil Chem Soc 41:280-285.
12. Budowski P, Markely KS. 1951. The chemical and physiological properties of sesame oil. Chem Rev 48:125-151.
13. Chan A, Cooley MA, Collins AM. 2001. Mast cells in the rat liver are phenotypically heterogeneous and exhibit features of immaturity. Immunol Cell Biol 79:35-40.
14. Chang FT, Chang SJ, Wu YY, Wang TN, Ko YC. 1995. Body mass index and hyperuricemia differences between aboriginal and nonaboriginal children in Taiwan. Kaohsiung J Med Sci 11:315-321.
15. Chang HY, Pan WH, Yeh WT, Tsai KS. 2001. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 28:1640-1646.
16. Chang YH, Garalla EJ. 1968. Suppression of urate crystal-induced canine joint inflammation by heterologous anti-polymorphonuclear leukocyte serum. Arthritis Rheum 11:145-150.
17. Chavali SR, Utsunomiya T, Forse RA. 2001. Increased survival after cecal ligation and puncture in mice consuming diets enriched with sesame seed oil. Crit Care Med 29:140-143.
18. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, et al. 2006. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116:2262-2271.
19. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, Akira S, Rock KL. 2006. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116:2262-2271.
20. Chen JJ, Yu BT. 1995. Values of blood sugar, cholesterol, uric acid and creatinine in adults of Taipei city. Acta Nephrol Society of Nephrology ROC 9:109-118.
21. Chen SY, Chen CL, Shen ML, Kamatani N. 2003.Trends in the clinical manifestations of gout in Taiwan. Rheumatology Oxford 42:1529-1533.
22. Chertov O, Yang D, Howard OM, Oppenheim JJ. 2000. Leukocyte granule proteins mobilize innate host defenses and adaptive immune responses. Immunol Rev 177:68-78.
23. Choi HK, Atkinson K, Karlson EW, Curhan G. 2005. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165:742-748.
24. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. 2004. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093-1103.
25. Choi HK, Mount DB, Reginato AM. 2005. Pathogenesis of gout. Ann Intern Med 143:499-516.
26. Chou P, Soong LN, Lin HY. 1993. Community-based epidemiological study on hyperuricemia in Pu-Li, Taiwan. J Formos Med Assoc 92:597-602.
27. Chu PY, Chien SP, Hsu DZ, Liu MY. 2010. Protective effect of sesamol on the pulmonary inflammatory response and lung injury in endotoxemic rats. Food Chem Toxicol 48:1821-1826.
28. Chu PY, Hsu DZ, Hsu PY, Liu MY. 2010. Sesamol down-regulates the lipopolysaccharide-induced inflammatory response by inhibiting nuclear factor-kappa B activation. Innate Immun 16:333-339.
29. Di Giovine FS, Malawista SE, Nuki G, Duff GW. 1987. Interleukin 1 (IL-1) as a mediator of crystal arthritis: stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL-1. J Immunol 138:3213-3218.
30. Di Giovine FS, Malawista SE, Thornton E, Duff GW. 1991. Urate crystals stimulate production of tumor necrosis factor -from human blood monocytes and synovial cells: cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 87:1375-1381.
31. Echtenacher B, Mannel DN, Hultner L. 1996. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77.
32. Edwards JCW, Sedgwick AD, Willoughby DA. 1981. The formation of a structure with the features of synovial lining by subcutaneous injection of sterile air. J Pathol 134:147-156.
33. Enerbäck L, Svensson I. 1980. Isolation of rat peritoneal mast cells by centrifugation on density gradients of Percoll. J Immunol Methods 39:135-145.
34. Ferreira J, Tapia G, Videla LA. 1998. Effects of the Kupffer cell inactivator gadolinium chloride on rat liver oxygen uptake and content of mitochondrial cytochromes. FEBS Lett 426:263-265.
35. Fields TR, Abramson SB, Weissmann G, Kaplan AP, Ghebrehiwet B. 1983. Activation of the alternative pathway of complement by monosodium urate crystals. Clin Immunol Immunopathol 26:249-257.
36. Giclas PC, Ginsberg MH, Cooper NR. 1979. Immunoglobulin G independent activation of the classical complement pathway by monosodium urate crystals. J Clin Invest 63:759-764.
37. Gilfillan AM, Rivera J. 2009. The tyrosine kinase network regulating mast cell activation. Immunol Rev 228:149-169.
38. Ginsberg MH, Kozin F, Chow D, May J, Skosey JL. 1977. Adsorption of polymorphonuclear leukocyte lysosomal enzymes to monosodium urate crystals. Arthritis Rheum 20:1538-1542.
39. Godfrey HP, Ilardi C, Engber W, Graziano FM. 1984. Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum 27:852-856.
40. Gotis-Graham I, McNeil HP. 1997. Mast cell responses in rheumatoid synovium: association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum 40:479-489.
41. Gotis-Graham I, Smith MD, Parker A, McNeil HP. 1998. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann Rheum Dis 57:664-671.
42. Granger DN, Kubes P. 1994. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 55:662-675.
43. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. 1989. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 32:1443-1452.
44. Hachicha M, Naccache PH, McColl SR. 1995. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 182:2019-2025.
45. Harris CM, Lloyd DC, Lewis J. 1995. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 48:1153-1158.
46. Harris MD, Siegel LB, Alloway JA. 1999. Gout and hyperuricemia. Am Fam Physician 59:925-934.
47. Hart PH. 2001. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 79:149-153. Review.
48. Haslett C, Savill JS, Whyte MK, Stern M, Dransfield I, Meagher LC. 1994. Granulocyte apoptosis and the control of inflammation. Philos Trans R Soc Lond B Biol Sci 345:327-333.
49. Hasselbacher P. 1979. Immunoelectrophoretic assay for synovial fluid C3 with correction for synovial fluid globulin. Arthritis Rheum 22:243-250.
50. Heneka MT, Löschmann PA, Gleichmann M, Weller M, Schulz JB, Wüllner U, Klockgether T. 1998. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J Neurochem 71:88-94.
51. Hou YC, Tsai SY, Liu IL, Yu CP, Chao PD. 2008. Metabolic transformation of sesamol and ex vivo effect on 2,2'-azo-bis(2-amidinopropane)dihydrochloride-induced hemolysis. J Agric Food Chem 56:9636-9640.
52. Huang HG, Sun YF, Hu M, Yuan GS, Wang Q, Liu YX. 2005. Characteristics of monosodium urate monohydrate crystal-induced acute arthritis in rats that mimicked human gouty arthritis. Bull Acad Mil Med Sci 29:538-542.
53. Hunder GG, McDuffie FC, Mullen BJ. 1977. Activation of complement components C3 and factor B in synovial fluids. J Lab Clin Med 89:160-171.
54. Hsu DZ, Li YH, Chien SP, Liu MY. 2004. Effects of sesame oil on oxidative stress and hepatic injury after cecal ligation and puncture in rats. Shock 21:466-469.
55. Hsu DZ, Liu CT, Li YH, Chu PY, Liu MY. 2010. Protective effect of daily sesame oil supplement on gentamicin-induced renal injury in rats. Shock 33:88-92.
56. Hsu DZ, Liu MY. 2004a. Effects of sesame oil on oxidative stress after the onset of sepsis in rats. Shock 22:582-585.
57. Hsu DZ, Su SB, Chien SP, Chianj PJ, Li YH, Lo YJ, Liu MY. 2005. Effect of sesame oil on oxidative-stress–associated renal injury in endotoxemic rats: involvement of nitric oxide and proinflammatory cytokines. Shock 24:276-280.
58. Jayaprakash V, Ansell G, Galler D. 2007. Colchicine overdose: the devil is in the detail. NZ Med J 120:U2402.
59. Jinbo T, Sakamoto T, Yamamoto S. 2002. Serum alpha2-macroglobulin and cytokine measurements in an acute inflammation model in rat. Lab Anim 36:153-157.
60. Kalia KK, Moossy JJ. 1993. Carpal tunnel release complicated by acute gout. Neurosurgery 33:1102-1103.
61. Kanevets U, Sharma K, Dresser K, Shi Y. 2009. A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol 182:1912-1918.
62. Kanwar S, Kubes P. 1994. Mast cells contribute to ischemia-reperfusion-induced granulocyte infiltration and intestinal dysfunction. Am J Physiol 267:316-321.
63. Kaur IP, Saini A. 2000. Sesamol exhibits antimutagenic activity against oxygen species mediated mutagenicity. Mutat Res 470:71-76.
64. Kellermeyer RW, Naff GB. 1975. Chemical mediators of inflammation in acute gouty arthritis. Arthritis Rheum 18:765-770.
65. Kubes P, Grabger DN. 1996. Leukocyte-endothelial cell interactions evoked by mast cells. Cardiovasc Res 32:699-708.
66. Kubes P, Kanwar S, Niu X-F, Gaboury J. 1993. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J 7:1293-1299.
67. Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, Kinne R. 2004. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis 63:774-784.
68. Kuo TP. 1964. Gout in the tropical Taiwan. J Form Med Assoc 63:415-426.
69. Liebman SE, Taylor JG, Bushinsky DA. 2007. Uric acid nephrolithiasis. Curr Rheumatol Rep 9:251-257.
70. Liote F, Ea HK. 2006. Gout: update on some pathogenic and clinical aspects. Rheum Dis Clin North Am 32:295-311.
71. Malaviya R, Ikeda T, Ross E, Abraham SN. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-. Nature 81:77-80.
72. Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute gout. Arthritis Rheum 2009 60:281-289.
73. Martin WJ, Harper JL. 2009. Innate inflammation and resolution in acute gout. Immunol Cell Biol 88:15-19.
74. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. 2006. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-241.
75. McNeil HP, Adachi R, Stevens RL. 2007. Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense. J Biol Chem 282:20785-20789. Review.
76. Metcalfe DD. 2008. Mast cells and mastocytosis. Blood 112:946-956.
77. Metcalfe DD, Baram D and Mekori YA. 1997. Mast cells. Physiol Rev 77: 1033-1079.
78. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. 2005. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 64:267-272.
79. Mullaly SC, and Kubes P. 2007. Mast cell-expressed complement receptor, not TLR2, is the main detector of zymosan in peritonitis. Eur. J. Immunol 37: 224-234.
80. Naff GB, Byers PH. 1973. Complement as a mediator of inflammation in acute gouty arthritis. I. Studies on the reaction between human serum complement and sodium urate crystals. J Lab Clin Med 81:747-760.
81. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. 2006. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 33:104-109.
82. Nishimura A, Akahoshi T, Takahashi M, Takagishi K, Itoman M, Kondo H, Takahashi Y, Yokoi K, Mukaida N, Matsushima K. 1997. Attenuation of monosodium urate crystal-induced arthritis in rabbits by a neutralizing antibody against interleukin-8. J Leukoc Bio 62:444-449.
83. Nuki G, Simkin PA. 2006. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 8 (suppl 1): S1.
84. Pekin Jr TJ, Zvaifler NJ. 1964. Hemolytic complement in synovial fluid. J Clin Invest 43:1372-1382.
85. Phelps P, McCarty DJ Jr. 1966. Crystal-induced inflammation in canine joints. II. Importance of polymorphonuclear leukocytes. J Exp Med 124:115-126.
86. Pittman JR, BrossMH. 1999. Diagnosis andmanagement of gout. Am Fam Physician 59:1799-1806.
87. Popa-Nita O, Naccache PH. 2010. Crystal-induced neutrophil activation. Immunol Cell Biol 88:32-40. Review.
88. Roberge CJ, Grassi J, De Medicis R, Frobert Y, Lussier A, Naccache PH et al. 1991. Crystal-neutrophil interactions lead to interleukin-1 synthesis. Agents Actions 34:38-41.
89. Roberge CJ, de Medicis R, Dayer JM, Rola-Pleszczynski M, Naccache PH, Poubelle PE. 1994. Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immunol 152: 5485-5494.
90. Roberge CJ, Gaudry M, de Medicis R, Lussier A, Poubelle PE, Naccache PH. 1993. Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 92:1722-1729.
91. Romano M, Faggioni R, Sironi M, Sacco S, Echtenacher B, Di Santo E, Salmona M, Ghezzi P. 1997. Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumor necrosis factor. Mediators Inflamm 6:32-38.
92. Romas E, Gillespie MT. 2006. Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin North Am 32:759-773.
93. Rose DM, Sydlaske AD, Agha-Babakhani A, Johnson K, Terkeltaub R. 2006. Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. Arthritis Rheum 54:3363-3371.
94. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. 1991. Incidence and risk factors for gout in white men. JAMA 266:3004-3007.
95. Rull M, Claybume G, Sieck M, Schumacher HR. 2003. 1ntra-articular corticosteroid preparations: different characteristics and their effect during ilflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology (Oxford) 42: l093-1100.
96. Russell IJ, Mansen C, Kolb LM, Kolb WP. 1982. Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface. Clin Immunol Immunopathol 24:239-250.
97. Saag KG, Choi H. 2006. Epidemiology, risk factors, and lifestyle modifi cations for gout. Arthritis Res Ther 8 (suppl 1): S2.
98. Schiltz C, Lioté F, Prudhommeaux F, Meunier A, Champy R, Callebert J, Bardin T. 2002. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum 46:1643-1650.
99. Schlesinger N. 2007. Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opin Drug Saf 6:625-629.
100. Schlesinger N, Schumacher R, Catton M, Maxwell L. 2006. Colchicine for acute gout. Cochrane Database Syst Rev 4: CD006190.
101. Schumacher HR, Reginato AJ. 1991. Atlas of Synovial Fluid Analysis and Crystal Identification. 1st edition. Philadelphia: Lea and Fiebiger.
102. Seegmiller JE, Howell RR, Malawista SE. 1962. The inflammatory reaction to sodium urate. JAMA 180:469-475.
103. Shefield FJ. 1963. Rheumatoid arthritis and gout: a study on Taiwan. J Form Med Assoc 62:435-439.
104. Sillaber C, Bevec D, Butterfield JH, Heppner C, Valenta R, Scheiner O, Kraft D, Lechner K, Bettelheim P, Valent P. 1993. Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. Exp Hematol 21:1271-1275.
105. Smirnova IV, Bittel DC, Ravindra R, Jiang H, Andrews GK. 2000. Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. J Biol Chem 275:9377-9384.
106. Sonntag NOV. 1981. Composition and characteristics of individual fats and oils. In: Baileys industrial oil and fat products. 4th ed., New York 289-477.
107. Staa TP, Leufkens HG, Cooper C. 2002. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777-787.
108. Strobl H, Scheinecker C, Csmarits B, Majdic O, Knapp W. 1995. Flow cytometric analysis of intracellular CD68 molecule expression in normal and malignant haemopoiesis. Br J Haematol 90:774-782.
109. Terkeltaub, R. 2003. Clinical practice. Gout. N. Engl. J. Med. 349:647-655.
110. Terkeltaub R, Baird S, Sears P, Santiago R, Boisvert W1998. The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate crystal–induced gouty synovitis. Arthritis Rheum 41:900-999.
111. Terkeltaub R, Tenner AJ, Kozin F, Ginsberg MH. 1983. Plasma protein binding by monosodium urate crystals. Analysis by two-dimensional gel electrophoresis. Arthritis Rheum 26:775-783.
112. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. 1991. Monocyte-derived neutrophil chemotactic factor/ interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 34:894-903.
113. Tramontini N, Huber C, Liu-Bryan R, Terkeltaub RA, Kilgore KS. 2004. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 50:2633-2639.
114. van Rooijen GJ, Moloney MM. 1995. Plant seed oil-bodies as carriers for foreign proteins. Biotechnology 13:72-77.
115. Varughese G, Varughese A, Tahrani A. 2007. Colchicine: time to rethink. NZ Med J 120:e31.
116. Wallace K, Riedel A, Joseph-Ridge N, Wortmann R. 2004. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582-1587.
117. Webster ME, Maling HM, Zweig MH, Williams MA, Anderson Jr W. 1972. Urate crystal induced inflammation in the rat: evidence for the combined actions of kinins, histamine and components of complement. Immunol Commun 1:185-198.
118. Wershil BK, Murakami T, Galli SJ. 1988. Mast cell-dependent amplification of an immunologically nonspecific inflammatory response. Mast cells are required for the full expression of cutaneous acute inflammation induced by phorbol 12-myristate 13-acetate. J Immunol 140:2356-2360.
119. Wortmann RL. 2008. Gout and hyperuricemia. In: Firestein G, ed. Kelley’s Textbook of Rheumatology Philadelphia: Saunders Elsevier: pp. 1481-1524.
120. Wyngaarden JB, Kelly WN. 1972. Gout and hyperuricemia. New York: Grune & Stratton 1:34-36.
121. Yang PC, Berin MC, Yu L, Perdue MH. 2001. Mucosal pathophysiology and inflammatory changes in the late phase of the intestinal allergic reaction in the rat. Am J Pathol 158:681-690.
122. Yu KH, Luo SF. 2003. Younger age of onset of gout in Taiwan. Rheumatology (Oxford) 42:166-170.
123. Zamorano J, Mora AL, Boothby M, Keegan AD. 2001. NF-kappa B activation plays an important role in the IL-4-induced protection from apoptosis. Int Immunol 13:1479-1487.
124. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T. 2006. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312-1324.
125. Zurier RB. 1993. Fatty acids, inflammation and immune responses. Prostaglandins Leukotrienes and Essential Fatty Acids 48:57-62.